UCSF Navigation Bar

UCSF Departments of Pathology & Laboratory Medicine Home Page

Lab Manual for UCSF Clinical Laboratories

Lab Manual for SFGH

Internal Resources

Click here for more information about laboratory operations and procedures

If you have additional questions regarding this test, please call: 415-353-1667

Search Our Test Menu

ALK Gene Rearrangement FISH

Item Value
Approval req'd? No
Available Stat? No
Test code
Performed by Clinical Cancer Genomics Laboratory (CCGL)
In House Availability Run 1-2 times per week as needed
Method Fluorescent in-situ hybridization (break apart FISH)
Collection Instructions For UCSF Samples (from remote sites) Click here for sample collection instructions

For NON-UCSF Samples Click here for Requisition form & Account set-up instructions. Note we only do institutional billing.
Container type
Sample type Formalin-fixed, paraffin-embedded tissue on three (3) unstained slides (5 microns thick) on charged glass. One adjacent hematoxylin and eosin stained (H&E) slide should also be included. Slides should be labeled with pathology case number and block identification.
Preferred volume 3 unstained slides
Min. Volume 1 unstained slide
UCSF Rejection Criteria All required slides not included. Insufficient tumor present on slide as determined by pathologist. Slides not labeled or not accompanied by completed requisition form.
Processing notes Contact CCGL at 415-502-3252 and inform them that a sample is available for pickup and your location.
Units % cells with brerakapart signals
Normal range < 15%
Stability Slides are stable indefinitely at room temperature
Turn around times 10-14 days
Additional information An interpretation of this test by a laboratory physician will automatically be performed and billed for separately.

ALK gene rearrangement testing by FISH is designed to detect the translocations of ALK gene in non-small cell lung cancer (NSCLC). This test is used to identify those patients eligible for treatment with XALKORI¨(crizotinib).

The clinical interpretation of this test should be evaluated within the context of the patient's medical history, other diagnostic tests, and the histologic and immunohistochemical features of the tumor.

The test was validated by the UCSF Clinical Cancer Genomics Laboratory (CCGL) to confirm performance characteristics, in compliance with current guidelines for clinical implementation
LDT or Mod FDA? Yes
Last Updated 12/15/2015 1:28:27 PM
Entry Number 1602
UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center